Skip to content
PubMed This is a summary of 100 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 100 referenced papers

Top Authors

Alexander C. Ford
University of Leeds
John F. Cryan
University College Cork
Emeran A. Mayer
Vanderbilt University
Brian E. Lacy
Jacksonville College
Magnus Simrén
University of North Carolina at Chapel Hill
Douglas A. Drossman
University of North Carolina at Chapel Hill
Kara Gross Margolis
New York University
William D. Chey
University of Michigan
Christopher J. Black
University of Leeds

Top Institutions

Ranked by publications Top 10 institutions
08

University of California, Los Angeles

Los Angeles, United States

149 papers

References

References (100)
  1. 1

    Two gastrointestinal conditions with similar symptoms and endoscopic appearance: irritable bowel syndrome and microscopic colitis.

    Şimşek Z, Tuncer NC, Alagüzlü H, et al.

    Turkish journal of medical sciences 2015; (45(2)):393-7 doi:10.3906/sag-1401-88.

    PMID: 26084132
  2. 2

    [Evolution of ideas on microscopic colitis].

    Maev IV, Kucheryavyi YA, Andreev DN, Cheremushkin SV

    Terapevticheskii arkhiv 2015; (87(4)):69-76 doi:10.17116/terarkh201587469-76.

    PMID: 26087638
  3. 3

    Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.

    Pimentel M

    Alimentary pharmacology & therapeutics 2016; (43 Suppl 1()):37-49 doi:10.1111/apt.13437.

    PMID: 26618924
  4. 4

    Review article: bile acid diarrhoea - pathogenesis, diagnosis and management.

    Mottacki N, Simrén M, Bajor A

    Alimentary pharmacology & therapeutics 2016; (43(8)):884-898 doi:10.1111/apt.13570.

    PMID: 26913381
  5. 5

    New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

    Foxx-Orenstein AE

    Therapeutic advances in gastroenterology 2016; (9(3)):354-75 doi:10.1177/1756283X16633050.

    PMID: 27134665
  6. 6

    Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome.

    Patel A, Hasak S, Cassell B, et al.

    Alimentary pharmacology & therapeutics 2016; (44(3)):246-58 doi:10.1111/apt.13677.

    PMID: 27240555
  7. 7

    Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome.

    Peters SL, Yao CK, Philpott H, et al.

    Alimentary pharmacology & therapeutics 2016; (44(5)):447-59 doi:10.1111/apt.13706.

    PMID: 27397586
  8. 8

    Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

    Lembo A, Pimentel M, Rao SS, et al.

    Gastroenterology 2016; (151(6)):1113-1121 doi:10.1053/j.gastro.2016.08.003.

    PMID: 27528177
  9. 9

    Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption.

    Peleman C, Camilleri M, Busciglio I, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2017; (15(5)):720-727.e1 doi:10.1016/j.cgh.2016.11.012.

    PMID: 27856362
  10. 10

    Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study.

    Xu XJ, Zhang YL, Liu L, et al.

    Alimentary pharmacology & therapeutics 2017; (45(1)):100-114 doi:10.1111/apt.13848.

    PMID: 27862119
  11. 11

    The Place of Stress and Emotions in the Irritable Bowel Syndrome.

    Pellissier S, Bonaz B

    Vitamins and hormones 2017; (103()):327-354 doi:10.1016/bs.vh.2016.09.005.

    PMID: 28061975
  12. 12

    Molecular pathogenicity of novel sucrase-isomaltase mutations found in congenital sucrase-isomaltase deficiency patients.

    Gericke B, Amiri M, Scott CR, Naim HY

    Biochimica et biophysica acta. Molecular basis of disease 2017; (1863(3)):817-826 doi:10.1016/j.bbadis.2016.12.017.

    PMID: 28062276
  13. 13

    Improved Starch Digestion of Sucrase-deficient Shrews Treated With Oral Glucoamylase Enzyme Supplements.

    Nichols BL, Avery SE, Quezada-Calvillo R, et al.

    Journal of pediatric gastroenterology and nutrition 2017; (65(2)):e35-e42 doi:10.1097/MPG.0000000000001561.

    PMID: 28267073
  14. 14

    Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros.

    Ghoshal UC

    Journal of neurogastroenterology and motility 2017; (23(3)):334-340 doi:10.5056/jnm17020.

    PMID: 28672432
  15. 15

    Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study.

    Vork L, Weerts ZZRM, Mujagic Z, et al.

    Neurogastroenterology and motility 2018; (30(2)) doi:10.1111/nmo.13189.

    PMID: 28804974
  16. 16

    Clinical Characteristics of Disaccharidase Deficiencies Among Children Undergoing Upper Endoscopy.

    Cohen SA, Oloyede H, Gold BD, et al.

    Journal of pediatric gastroenterology and nutrition 2018; (66 Suppl 3()):S56-S60 doi:10.1097/MPG.0000000000001961.

    PMID: 29762380
  17. 17

    [Diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols, and quality of life in patients with irritable bowel syndrome in Colombia].

    Yepes IJ, Múnera MN, Martelo C

    Biomedica : revista del Instituto Nacional de Salud 2018; (38(0)):61-68 doi:10.7705/biomedica.v38i0.3443.

    PMID: 29809329
  18. 18

    Dietary Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) and Gastrointestinal Disease.

    Vakil N

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2018; (33(4)):468-475 doi:10.1002/ncp.10108.

    PMID: 29870082
  19. 19

    Pathogenic Factors in Postinfectious Irritable Bowel Syndrome - An Update.

    Iacob T, Ţăţulescu DF, Cijevschi Prelipcean C, Dumitraşcu DL

    Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 2016; (120(3)):515-21.

    PMID: 30044574
  20. 20

    Small Intestinal Bacterial Overgrowth Syndrome Prevalence in Romanian Patients with Inflammatory Bowel Disease.

    Andrei M, Gologan S, Stoicescu A, et al.

    Current health sciences journal 2016; (42(2)):151-156 doi:10.12865/CHSJ.42.02.06.

    PMID: 30568826
  21. 21

    Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review.

    Khetpal N, Yadav L, Khalid S, Kumar R

    Cureus 2018; (10(12)):e3747 doi:10.7759/cureus.3747.

    PMID: 30820368
  22. 22

    Effect of Three Diets (Low-FODMAP, Gluten-free and Balanced) on Irritable Bowel Syndrome Symptoms and Health-Related Quality of Life.

    Paduano D, Cingolani A, Tanda E, Usai P

    Nutrients 2019; (11(7)) doi:10.3390/nu11071566.

    PMID: 31336747
  23. 23

    Relationship between Stool Form and Quality of Life in Patients with Chronic Constipation: An Internet Questionnaire Survey.

    Ohkubo H, Yoshihara T, Misawa N, et al.

    Digestion 2021; (102(2)):147-154 doi:10.1159/000502815.

    PMID: 31574514
  24. 24

    Stool Consistency: Looking Beyond the Bristol Stool Form Scale.

    Vork L, Wilms E, Penders J, Jonkers DMAE

    Journal of neurogastroenterology and motility 2019; (25(4)):625 doi:10.5056/jnm19086.

    PMID: 31587553
  25. 25

    Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.

    Brenner DM, Sayuk GS

    Advances in therapy 2020; (37(1)):83-96 doi:10.1007/s12325-019-01116-z.

    PMID: 31707713
  26. 26

    Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.

    Rao SSC, Xiang X, Yan Y, et al.

    Alimentary pharmacology & therapeutics 2020; (51(12)):1332-1341 doi:10.1111/apt.15772.

    PMID: 32406112
  27. 27

    The Role of Bile Acids in Chronic Diarrhea.

    Camilleri M, Vijayvargiya P

    The American journal of gastroenterology 2020; (115(10)):1596-1603 doi:10.14309/ajg.0000000000000696.

    PMID: 32558690
  28. 28

    Preliminary Study on the Tears Oxidative Stress Status and Sleep Disturbances in Irritable Bowel Syndrome Patients.

    Balmus IM, Cojocariu RO, Ciobica A, et al.

    Oxidative medicine and cellular longevity 2020; (2020()):4690713 doi:10.1155/2020/4690713.

    PMID: 32566082
  29. 29

    Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial.

    Basnayake C, Kamm MA, Stanley A, et al.

    The lancet. Gastroenterology & hepatology 2020; (5(10)):890-899 doi:10.1016/S2468-1253(20)30215-6.

    PMID: 32679040
  30. 30

    Management of Irritable Bowel Syndrome: Physician-Dietitian Collaboration.

    Ireton-Jones C, Weisberg MF

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2020; (35(5)):826-834 doi:10.1002/ncp.10567.

    PMID: 32786046
  31. 31

    Behavioral and Diet Therapies in Integrated Care for Patients With Irritable Bowel Syndrome.

    Chey WD, Keefer L, Whelan K, Gibson PR

    Gastroenterology 2021; (160(1)):47-62 doi:10.1053/j.gastro.2020.06.099.

    PMID: 33091411
  32. 32

    Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome?

    Bellini M, Tonarelli S, Mumolo MG, et al.

    Nutrients 2020; (12(11)) doi:10.3390/nu12113368.

    PMID: 33139629
  33. 33

    [Is the diet low in FODMAP really effective and safe for irritable bowel syndrome?: A scoping review].

    Sebastián Domingo JJ, Sánchez Sánchez C

    Semergen 2020; (46(8)):566-576 doi:10.1016/j.semerg.2020.07.010.

    PMID: 33153877
  34. 34

    Serum 7-alfa-hydroxy-4-cholesten-3-one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease.

    Lyutakov I, Lozanov V, Sugareva P, et al.

    European journal of gastroenterology & hepatology 2021; (33(3)):380-387 doi:10.1097/MEG.0000000000001925.

    PMID: 33177381
  35. 35

    Appropriateness of colonoscopy at a tertiary care centre - are we overdoing gastrointestinal endoscopy?

    Čustović N, Džananović L, Rašić I, et al.

    Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina 2021; (18(1)):84-89 doi:10.17392/1248-21.

    PMID: 33219637
  36. 36

    ACG Clinical Guideline: Management of Irritable Bowel Syndrome.

    Lacy BE, Pimentel M, Brenner DM, et al.

    The American journal of gastroenterology 2021; (116(1)):17-44 doi:10.14309/ajg.0000000000001036.

    PMID: 33315591
  37. 37

    Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea-predominant irritable bowel syndrome: A prospective, randomized trial.

    Goyal O, Batta S, Nohria S, et al.

    Journal of gastroenterology and hepatology 2021; (36(8)):2107-2115 doi:10.1111/jgh.15410.

    PMID: 33464683
  38. 38

    The Microbiota-Gut-Brain Axis: From Motility to Mood.

    Margolis KG, Cryan JF, Mayer EA

    Gastroenterology 2021; (160(5)):1486-1501 doi:10.1053/j.gastro.2020.10.066.

    PMID: 33493503
  39. 39

    Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis.

    Shah ED, Salwen-Deremer JK, Gibson PR, et al.

    MDM policy & practice 2021; (6(1)):2381468320978417 doi:10.1177/2381468320978417.

    PMID: 33521290
  40. 40

    Prevalence of biliary acid malabsorption in patients with chronic diarrhoea of functional characteristics: a prospective study.

    Flores V, Martínez-Lozano H, Bighelli F, et al.

    BMC gastroenterology 2021; (21(1)):56 doi:10.1186/s12876-021-01637-4.

    PMID: 33563227
  41. 41

    Sucrase-Isomaltase Deficiency Causing Persistent Bloating and Diarrhea in an Adult Female.

    Chiruvella V, Cheema A, Arshad HMS, et al.

    Cureus 2021; (13(4)):e14349 doi:10.7759/cureus.14349.

    PMID: 33972906
  42. 42

    A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome.

    Nulsen B, LeBrett W, Drossman DA, Chang L

    Alimentary pharmacology & therapeutics 2021; (54(3)):281-291 doi:10.1111/apt.16467.

    PMID: 34148256
  43. 43

    Chronic stress and poor sleeping habits are associated with self-reported IBS and poor psychological well-being in the general population.

    Zejnelagic J, Ohlsson B

    BMC research notes 2021; (14(1)):280 doi:10.1186/s13104-021-05688-4.

    PMID: 34294119
  44. 44

    Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation.

    Liu JJ, Brenner DM

    Gastroenterology clinics of North America 2021; (50(3)):639-653 doi:10.1016/j.gtc.2021.04.004.

    PMID: 34304792
  45. 45

    Pain and psyche in a patient with irritable bowel syndrome: chicken or egg? A time series case report.

    Engel F, Stadnitski T, Stroe-Kunold E, et al.

    BMC gastroenterology 2021; (21(1)):309 doi:10.1186/s12876-021-01879-2.

    PMID: 34344311
  46. 46

    Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review.

    Tang HY, Jiang AJ, Wang XY, et al.

    Annals of translational medicine 2021; (9(14)):1187 doi:10.21037/atm-21-2779.

    PMID: 34430628
  47. 47

    Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome.

    Staudacher HM, Rossi M, Kaminski T, et al.

    Neurogastroenterology and motility 2022; (34(4)):e14241 doi:10.1111/nmo.14241.

    PMID: 34431172
  48. 48

    Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders.

    Eijsbouts C, Zheng T, Kennedy NA, et al.

    Nature genetics 2021; (53(11)):1543-1552 doi:10.1038/s41588-021-00950-8.

    PMID: 34741163
  49. 49

    Commonly used biomarkers do not contribute to diagnosing irritable bowel syndrome.

    Kramer S, Masclee AAM, Jebbink RJA, Tack GJ

    European journal of gastroenterology & hepatology 2022; (34(3)):302-307 doi:10.1097/MEG.0000000000002312.

    PMID: 34775459
  50. 50

    Review article: current and future treatment approaches for pain in IBS.

    Paine P

    Alimentary pharmacology & therapeutics 2021; (54 Suppl 1()):S75-S88 doi:10.1111/apt.16550.

    PMID: 34927753
  51. 51

    Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).

    Nee J, Lembo A

    Alimentary pharmacology & therapeutics 2021; (54 Suppl 1()):S63-S74 doi:10.1111/apt.16625.

    PMID: 34927757
  52. 52

    AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.

    Chang L, Sultan S, Lembo A, et al.

    Gastroenterology 2022; (163(1)):118-136 doi:10.1053/j.gastro.2022.04.016.

    PMID: 35738724
  53. 53

    AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.

    Lembo A, Sultan S, Chang L, et al.

    Gastroenterology 2022; (163(1)):137-151 doi:10.1053/j.gastro.2022.04.017.

    PMID: 35738725
  54. 54

    Do Socio-Demographics Play a Role in the Prevalence of Red Flags and Pursuant Colonoscopies in Patients With Irritable Bowel Syndrome?

    Mittal A, Gupta S, Afridi F, et al.

    Cureus 2022; (14(5)):e25137 doi:10.7759/cureus.25137.

    PMID: 35747043
  55. 55

    Impact of Rome IV irritable bowel syndrome on work and activities of daily living.

    Goodoory VC, Ng CE, Black CJ, Ford AC

    Alimentary pharmacology & therapeutics 2022; (56(5)):844-856 doi:10.1111/apt.17132.

    PMID: 35794733
  56. 56

    Irritable Bowel Syndrome: A Multifaceted World Still to Discover.

    Bassotti G

    Journal of clinical medicine 2022; (11(14)) doi:10.3390/jcm11144103.

    PMID: 35887869
  57. 57

    Organic colonic lesions in patients with irritable bowel syndrome: A comparative study.

    Ejtehadi F, Anbardar MH, Imanieh MH, et al.

    Revista de gastroenterologia de Mexico (English) 2023; (88(3)):208-213 doi:10.1016/j.rgmxen.2022.07.007.

    PMID: 35906157
  58. 58

    Modest Conformity Between Self-Reporting of Bristol Stool Form and Fecal Consistency Measured by Stool Water Content in Irritable Bowel Syndrome and a FODMAP and Gluten Trial.

    Nordin E, Hellström PM, Brunius C, Landberg R

    The American journal of gastroenterology 2022; (117(10)):1668-1674 doi:10.14309/ajg.0000000000001942.

    PMID: 36087104
  59. 59

    Healthy sleep, mental health, genetic susceptibility, and risk of irritable bowel syndrome.

    Liu M, Ye Z, Wu Q, et al.

    Journal of affective disorders 2023; (331()):25-32 doi:10.1016/j.jad.2023.03.033.

    PMID: 36934852
  60. 60

    Differential Diagnosis of Chronic Diarrhea: An Algorithm to Distinguish Irritable Bowel Syndrome With Diarrhea From Other Organic Gastrointestinal Diseases, With Special Focus on Exocrine Pancreatic Insufficiency.

    Brenner DM, Domínguez-Muñoz JE

    Journal of clinical gastroenterology 2023; (57(7)):663-670 doi:10.1097/MCG.0000000000001855.

    PMID: 37115854
  61. 61

    Effects of a Low-FODMAP Diet on Irritable Bowel Syndrome in Both Children and Adults-A Narrative Review.

    Morariu ID, Avasilcai L, Vieriu M, et al.

    Nutrients 2023; (15(10)) doi:10.3390/nu15102295.

    PMID: 37242178
  62. 62

    Prospective comparison of diagnostic tests for bile acid diarrhoea.

    Borup C, Vinter-Jensen L, Jørgensen SPG, et al.

    Alimentary pharmacology & therapeutics 2024; (59(1)):39-50 doi:10.1111/apt.17739.

    PMID: 37794830
  63. 63

    Fecal calprotectin in cirrhosis-Does "ESR" of the intestine measure the liver dysfunction too?

    Jena A, Sharma V, Dutta U

    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2023; (42(6)):754-756 doi:10.1007/s12664-023-01481-2.

    PMID: 37999894
  64. 64

    Post-infection irritable bowel syndrome following Coronavirus disease-19: A systematic review and meta-analysis.

    Mathur A, Shams U, Mishra P, et al.

    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2024; (43(3)):557-566 doi:10.1007/s12664-023-01486-x.

    PMID: 38261245
  65. 65

    Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

    Lembo AJ, Chey WD, Harris LA, et al.

    The American journal of gastroenterology 2024; (119(5)):937-945 doi:10.14309/ajg.0000000000002685.

    PMID: 38294158
  66. 66

    Anxiety-Related Factors Associated With Symptom Severity in Irritable Bowel Syndrome in Jazan, Saudi Arabia.

    Alhazmi A, Darraj H, Abdali H, et al.

    Cureus 2024; (16(2)):e53549 doi:10.7759/cureus.53549.

    PMID: 38445128
  67. 67

    Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When.

    Hanna-Jairala I, Drossman DA

    The American journal of gastroenterology 2024; (119(7)):1272-1284 doi:10.14309/ajg.0000000000002800.

    PMID: 38595149
  68. 68

    Intensive short-term dynamic psychotherapy for irritable bowel syndrome: a randomized controlled trial examining improvements in emotion regulation, defense mechanisms, quality of life, and IBS symptoms.

    Shafiei F, Dehghani M, Lavasani FF, et al.

    Frontiers in psychology 2024; (15()):1293150 doi:10.3389/fpsyg.2024.1293150.

    PMID: 38605838
  69. 69

    [Bile Acid Diarrhea].

    Kim HJ, Kim HJ

    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2024; (83(4)):133-142 doi:10.4166/kjg.2023.119.

    PMID: 38659249
  70. 70

    All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable Bowel Syndrome.

    Eswaran S, Jencks KJ, Singh P, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(2)):351-358.e5 doi:10.1016/j.cgh.2024.03.047.

    PMID: 38729390
  71. 71

    Causative Factors, Clinical Manifestations, and Therapeutic Strategies for Irritable Bowel Syndrome.

    Anand K, Khatib MN

    Cureus 2024; (16(4)):e58728 doi:10.7759/cureus.58728.

    PMID: 38779277
  72. 72

    Impact of mechanical barrier damage and interleukin-17 on symptoms in patients with post-infectious irritable bowel syndrome.

    Zhao J, Dai Y, Tian J, et al.

    British journal of hospital medicine (London, England : 2005) 2024; (85(7)):1-13 doi:10.12968/hmed.2024.0114.

    PMID: 39078895
  73. 73

    Congenital Sucrase-Isomaltase Deficiency: Same Mutation with Different Clinical Presentations.

    İryancı Fİ, Güven B, Çakır M

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2024; (35(4)):343-349 doi:10.5152/tjg.2024.23250.

    PMID: 39128102
  74. 74

    Functional Bowel Disorder Management in Routine Practice with Tips for Hot Topics: Expert Opinion Review.

    Akyüz F, Çelebi A, Doğan İ, et al.

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2024; (35(6)):423-439 doi:10.5152/tjg.2024.24029.

    PMID: 39128123
  75. 75

    The sucrose challenge symptoms test optimized for diagnosis of congenital sucrase isomaltase deficiency.

    Street K, Tao W, Cash B, et al.

    PloS one 2024; (19(9)):e0310705 doi:10.1371/journal.pone.0310705.

    PMID: 39292728
  76. 76

    Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT.

    Wright-Hughes A, Ford AC, Alderson SL, et al.

    Health technology assessment (Winchester, England) 2024; (28(66)):1-161 doi:10.3310/BFCR7986.

    PMID: 39397570
  77. 77

    Differences in Prevalence and Psychosocial Characteristics of Irritable Bowel Syndrome According to Rome III and Rome IV Criteria in Medical and Nursing Students.

    Park JH, Jeong HJ, Lee KE, et al.

    Journal of neurogastroenterology and motility 2024; (30(4)):491-500 doi:10.5056/jnm22067.

    PMID: 39397626
  78. 78

    Bile acid malabsorption investigated by selenium-75-homocholic acid taurine (75SeHCAT) scans, a retrospective single-centre experience.

    Vulsteke F, De Gersem R, Arts J, Vanuytsel T

    Acta gastro-enterologica Belgica 2024; (87(3)):381-387 doi:10.51821/87.3.13036.

    PMID: 39411791
  79. 79

    Chronic Diarrhea Owing to Microscopic Colitis: A Cohort Study with Insights into Diagnostic Challenges and Size of the Problem.

    Gad AI, Salem SM, Nofal HA, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(20)) doi:10.3390/diagnostics14202333.

    PMID: 39451656
  80. 80

    Recent advances in clinical practice: mastering the challenge-managing IBS symptoms in IBD.

    Wellens J, Sabino J, Vanuytsel T, et al.

    Gut 2025; (74(2)):312-321 doi:10.1136/gutjnl-2024-333565.

    PMID: 39532478
  81. 81

    The gut-brain axis and pain signalling mechanisms in the gastrointestinal tract.

    Meerschaert KA, Chiu IM

    Nature reviews. Gastroenterology & hepatology 2025; (22(3)):206-221 doi:10.1038/s41575-024-01017-9.

    PMID: 39578592
  82. 82

    Exploring congenital sucrase-isomaltase deficiency in autism spectrum disorder patients with irritable bowel syndrome symptoms: A prospective SI gene sequencing study.

    Zubarioglu T, Ulgen D, Akca-Yesil S, et al.

    Autism research : official journal of the International Society for Autism Research 2025; (18(1)):44-55 doi:10.1002/aur.3293.

    PMID: 39676735
  83. 83

    [Small intestine bacterial overgrowth: Myths and realities].

    Guardiola-Arévalo A, Mascort Roca J, Noguerol Álvarez M, et al.

    Atencion primaria 2025; (57(4)):103201 doi:10.1016/j.aprim.2024.103201.

    PMID: 39799751
  84. 84

    Impact of Positive Glucose, Lactose, and Fructose Hydrogen Breath Tests on Symptoms and Quality of Life in Irritable Bowel Syndrome.

    Loo QY, Chuah KH, Hian WX, et al.

    Journal of gastroenterology and hepatology 2025; (40(4)):884-890 doi:10.1111/jgh.16891.

    PMID: 39854015
  85. 85

    Attention in irritable bowel syndrome: A systematic review of affected domains and brain-gut axis interactions.

    Akbari R, Salimi Y, Dehghani-Aarani F, Rezayat E

    Journal of psychosomatic research 2025; (191()):112067 doi:10.1016/j.jpsychores.2025.112067.

    PMID: 40048890
  86. 86

    Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort).

    Olsen BC, Opheim R, Kristensen VA, et al.

    Inflammatory bowel diseases 2025; (31(10)):2704-2713 doi:10.1093/ibd/izaf047.

    PMID: 40063582
  87. 87

    Demystifying Carbohydrate Maldigestion: A Clinical Review.

    Cash BD, Patel D, Scarlata K

    The American journal of gastroenterology 2025; (120(4S)):1-11 doi:10.14309/ajg.0000000000003374.

    PMID: 40249016
  88. 88

    Diet, nutraceuticals, and lifestyle interventions for the treatment and management of irritable bowel syndrome.

    Memel ZN, Shah ND, Beck KR

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2025; (40(5)):1013-1030 doi:10.1002/ncp.11307.

    PMID: 40346863
  89. 89

    Sentiment analysis and topic modeling of social media data to explore public discourse on irritable bowel syndrome.

    Shankar R, Yip AW

    Scientific reports 2025; (15(1)):21550 doi:10.1038/s41598-025-08599-7.

    PMID: 40596686
  90. 90

    Psychometric properties of the Hungarian Visceral Sensitivity Index (VSI-H): insights from two cross-sectional studies on self-reported IBS and gluten-related conditions.

    Bertalan E, Horváth Z, Gajdos P, et al.

    BMC psychology 2025; (13(1)):679 doi:10.1186/s40359-025-02918-3.

    PMID: 40597234
  91. 91

    European Consensus on Functional Bloating and Abdominal Distension-An ESNM/UEG Recommendations for Clinical Management.

    Melchior C, Hammer H, Bor S, et al.

    United European gastroenterology journal 2025; (13(9)):1613-1651 doi:10.1002/ueg2.70098.

    PMID: 40844856
  92. 92

    Electroacupuncture at Baliao Points Attenuates Visceral Hypersensitivity in Irritable Bowel Syndrome via Gut-Microbiota-Mast Cell-TPRV1 Axis Modulation.

    Sun MY, Xing HH, Lin X, et al.

    Neurogastroenterology and motility 2025; (37(11)):e70137 doi:10.1111/nmo.70137.

    PMID: 40887796
  93. 93

    Rome III Versus Rome IV Criteria for Diagnosing Irritable Bowel Syndrome in a Southeast Asian Population: Insights From the Rome Foundation Global Epidemiology Study Household Survey.

    Simadibrata DM, Koo TH, Utari AP, et al.

    Journal of gastroenterology and hepatology 2026; (41(1)):168-179 doi:10.1111/jgh.70174.

    PMID: 41344821
  94. 94

    Prevalence of irritable bowel syndrome in medical students: a systematic review and meta-analysis.

    Ballena-Caicedo J, Zuzunaga-Montoya FE, Valladolid-Sandoval LAM, et al.

    Frontiers in medicine 2025; (12()):1714085 doi:10.3389/fmed.2025.1714085.

    PMID: 41473163
  95. 95

    An umbrella review of meta-analyses on the low-FODMAP diet in IBS.

    Bogdanowska-Charkiewicz D, Malinowska U, Daniluk J

    Frontiers in nutrition 2025; (12()):1714281 doi:10.3389/fnut.2025.1714281.

    PMID: 41550863
  96. 96

    The mediating role of resilience in the relationship between cognitive flexibility and psychological well-being in patients with irritable bowel syndrome: a cross-sectional study.

    Tamannaeifar MR, Shirani Z, Esmikhani M, Zaremohzzabieh Z

    BMC gastroenterology 2026; (26(1)).

    PMID: 41620640
  97. 97

    A multidisciplinary approach to the management of disorders of gut-brain interaction: psychopharmacology, psychotherapy, and diet.

    Barrera Flores FJ, Tamez JAG, Winkelman T, et al.

    Frontiers in gastroenterology (Lausanne, Switzerland) 2025; (4()) doi:10.3389/fgstr.2025.1637172.

    PMID: 41669534
  98. 98

    Depression, Anxiety and Quality of Life in Adults and Older Adults with Irritable Bowel Syndrome (IBS): Observational Analysis of MEPS National Database.

    Alwhaibi M, Almazrou SH

    Patient preference and adherence 2026; (20()):585772 doi:10.2147/PPA.S585772.

    PMID: 41710335
  99. 99

    Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses.

    Palenca I, Franzin SB, Pesce M, et al.

    Pharmacological reports : PR 2026; (78(3)):627-640 doi:10.1007/s43440-026-00830-0.

    PMID: 41729463
  100. 100

    Economic and humanistic burden of comorbid depression among individuals with irritable bowel syndrome in the non-institutionalized US adult population.

    Bhattacharya K, Arabshomali A, Lin LY, et al.

    Journal of affective disorders 2026; (408()):121854 doi:10.1016/j.jad.2026.121854.

    PMID: 42035802